BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3145743)

  • 1. Recombinant interferon gamma in the treatment of metastatic renal cell carcinoma. Results of a phase II trial.
    Otto U; Conrad S; Schneider AW; Klosterhalfen H
    Arzneimittelforschung; 1988 Nov; 38(11):1658-60. PubMed ID: 3145743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon.
    Small EJ; Weiss GR; Malik UK; Walther PJ; Johnson D; Wilding G; Kuzel T; Bajamonde A; Paton V
    Cancer J Sci Am; 1998; 4(3):162-7. PubMed ID: 9612597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.
    Gleave ME; Elhilali M; Fradet Y; Davis I; Venner P; Saad F; Klotz LH; Moore MJ; Paton V; Bajamonde A
    N Engl J Med; 1998 Apr; 338(18):1265-71. PubMed ID: 9562580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial.
    Schmidinger M; Steger G; Wenzel C; Locker GJ; Budinsky AC; Brodowicz T; Kramer G; Marberger M; Zielinski CC;
    J Immunother; 2001; 24(3):257-62. PubMed ID: 11394504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of recombinant interferon alpha-C in patients with metastatic renal cell carcinoma.
    Merimsky O; Inbar M; Merimsky E; Kovner F; Spitzer E; Laufer R; Braf Z; Chaitchik S
    Mol Biother; 1990 Sep; 2(3):155-9. PubMed ID: 2222899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant alpha-2 or gamma interferon in the treatment of metastatic renal cell carcinoma: results of two phase II/III trials.
    Otto U; Schneider AW; Conrad S; Klosterhalfen H
    Prog Clin Biol Res; 1990; 350():275-82. PubMed ID: 2117287
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
    Rinehart JJ; Malspeis L; Young D; Neidhart JA
    J Biol Response Mod; 1986 Aug; 5(4):300-8. PubMed ID: 3090208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma.
    Quesada JR; Kurzrock R; Sherwin SA; Gutterman JU
    J Biol Response Mod; 1987 Feb; 6(1):20-7. PubMed ID: 3104544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma.
    Bruntsch U; de Mulder PH; ten Bokkel Huinink WW; Clavel M; Drozd A; Kaye SB; Renard J; van Glabbeke M
    J Biol Response Mod; 1990 Jun; 9(3):335-8. PubMed ID: 2116500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase II study of recombinant human interferon gamma (S-6810) in renal cell carcinoma. Urological Cooperative Study Group of Recombinant Human Interferon Gamma (S-6810)].
    Machida T; Koiso K; Takaku F; Ogawa M
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):440-5. PubMed ID: 3101607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
    Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
    Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of metastatic kidney cancer with recombinant alpha-2 or gamma interferon. Results of 2 clinical phase II and III studies].
    Otto U; Schneider A; Denkhaus H; Conrad S
    Onkologie; 1988 Aug; 11(4):185-91. PubMed ID: 3141856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma.
    Kempf RA; Grunberg SM; Daniels JR; Skinner DG; Venturi CL; Spiegel R; Neri R; Greiner JM; Rudnick S; Mitchell MS
    J Biol Response Mod; 1986 Feb; 5(1):27-35. PubMed ID: 3958753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma].
    Hofmockel G; Wirth MP; Heimbach D; Frohmüller HG
    Urologe A; 1993 Jul; 32(4):290-4. PubMed ID: 8372410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
    Rinehart J; Malspeis L; Young D; Neidhart J
    Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.